Klotho Neurosciences, Inc. (KLTO) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Klotho Neurosciences reported revenue of $0. Net income was -$10.6M, or -$11.00 per diluted share. Operating activities generated -$5.9M of cash. At fiscal year end, Klotho Neurosciences held $9.6M in total assets against $129,764 in total liabilities, including $7.2M of cash and equivalents.
Open the full interactive Klotho Neurosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Klotho Neurosciences Key Stats
| Share Price | $5.54 |
|---|---|
| Market Cap | $14.0M |
| 52-Week Range | $2.85 – $33.00 |
| Shares Outstanding | 2.5 million (basic, 2026 Q2) |
Klotho Neurosciences Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$657,018 | -$1.3M | -$5.5M | -$7.1M |
| Pre-Tax Income | $1.5M | $2.0M | -$6.2M | -$10.6M |
| Income Tax | $243,070 | $690,572 | — | — |
| Net Income | $1.2M | $1.3M | -$6.2M | -$10.6M |
| Diluted EPS | $51.50 | $17.00 | -$16.00 | -$11.00 |
Klotho Neurosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.9M | -$1.3M | -$13.9M | -$3.7M |
| Diluted EPS | -$2.50 | -$0.03 | -$7.50 | -$1.50 |
Klotho Neurosciences Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | — | $172,535 | $63,741 | $7.2M |
| Current Assets | $440,158 | $199,530 | $157,811 | $7.3M |
| Total Assets | $118.2M | $19.5M | $2.5M | $9.6M |
| Current Liabilities | $506,241 | $2.3M | $1.2M | $76,764 |
| Total Liabilities | $4.9M | $8.2M | $1.3M | $129,764 |
| Shareholders' Equity | -$4.0M | -$7.4M | $1.2M | $9.5M |
Klotho Neurosciences Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$493,043 | -$1.3M | -$2.9M | -$5.9M |
| Cash From Investing | -$116.2M | $101.9M | -$123,497 | — |
| Cash From Financing | $117.0M | -$100.8M | $3.1M | $13.0M |
Figures from Klotho Neurosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Klotho Neurosciences financials page for every line item.
Klotho Neurosciences Company Profile
| Ticker | KLTO |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Omaha, Nebraska |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001907223 |
Frequently Asked Questions
What was Klotho Neurosciences' revenue in fiscal 2025?
Klotho Neurosciences (KLTO) reported revenue of $0 for fiscal 2025.
What is Klotho Neurosciences' annual revenue history?
Klotho Neurosciences' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Klotho Neurosciences' net income in fiscal 2025?
Klotho Neurosciences reported net income of -$10.6M for fiscal 2025.
What was Klotho Neurosciences' earnings per share (EPS) in fiscal 2025?
Klotho Neurosciences' diluted EPS was -$11.00 for fiscal 2025 (adjusted for any later stock splits).
What was Klotho Neurosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Klotho Neurosciences reported revenue of $0.
How many shares of Klotho Neurosciences are outstanding?
Klotho Neurosciences reported a weighted average of 2.5 million basic shares outstanding in 2026 Q2.
What is Klotho Neurosciences' market cap?
Based on its latest closing price, Klotho Neurosciences (KLTO) has a market capitalization of about $14.0M.
When does Klotho Neurosciences' fiscal year end?
Klotho Neurosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Klotho Neurosciences headquartered?
Klotho Neurosciences lists its business address in Omaha, Nebraska in its SEC filings.
Klotho Neurosciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →